Cystic Fibrosis
Conditions
Brief summary
The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with nonsense mutation cystic fibrosis
Detailed description
Cystic Fibrosis (CF) is a life threatening genetic disorder resulting from mutations found in the CF gene known as the cystic fibrosis transmembrane conductance regulator or CFTR. This defect prevents correct chloride absorption in and out of the cells The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
Interventions
DRUGAtaluren
ataluren
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial. 2. Age ≥6 years 3. Body weight ≥16 kg 4. Diagnosis of cystic fibrosis and documentation of the presence of a nonsense mutations of the CFTR gene, as determined by historical genotyping 5. Ability to perform a valid, reproducible spirometry with demonstration of a forced expiratory volume in 1second (FEV1) ≥30% and ≤90% of predicted for age, gender, and height. 6. If the subject is sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration 7. Willingness and ability to comply with all study procedures and assessments. 8. Currently being administered ivacaftor, either alone (Kalydeco) or in combination with lumacaftor (Orkambi)
Exclusion criteria
1. Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 2 weeks prior to screening. 2. Ongoing participation in any other therapeutic clinical trial. 3. Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 2 weeks prior to screening. 4. Ongoing inhaled tobramycin therapy. 5. Ongoing immunosuppressive therapy (other than corticosteroids up to 10mg/d equivalent of prednisone) 6. Ongoing warfarin, phenytoin, or tolbutamide therapy. 7. History of solid organ or hematological transplantation. 8. A history of positive hepatitis B surface antigen test, hepatitis C antibody test, or human immunodeficiency 9. Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 4 weeks prior to screening. 10. Pregnancy or breast-feeding. 11. Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day × number of years smoked). 12. Prior or ongoing medical condition (eg, renal failure, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FEV1 as a Measure of Lung Function | 1 year | effect of ataluren on lung function as assessed by spirometry and measured by percentage of Liters (minimum value would be .0% Liters and maximum value of liters is dependent from person to person). The higher the value the better the outcome. The measure will include the change from baseline to one year to report a change between the two measurement points |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Ataluren Administration dose of the drug administered (mg/kg body weight)
Ataluren: ataluren | 1 |
| Total | 1 |
Baseline characteristics
| Characteristic | Ataluren Administration |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 1 Participants |
| Age, Continuous | 31 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 1 Participants |
| Region of Enrollment United States | 1 participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 1 |
| other Total, other adverse events | 1 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
FEV1 as a Measure of Lung Function
effect of ataluren on lung function as assessed by spirometry and measured by percentage of Liters (minimum value would be .0% Liters and maximum value of liters is dependent from person to person). The higher the value the better the outcome. The measure will include the change from baseline to one year to report a change between the two measurement points
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Ataluren Administration | FEV1 as a Measure of Lung Function | .35 percentage of liters |